Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
作者： C Parrish , G B Scott , G Migneco , K J Scott , L P Steele
DOI: 10.1038/LEU.2015.88
关键词:
摘要: The naturally occurring oncolytic virus (OV), reovirus, replicates in cancer cells causing direct cytotoxicity, and can activate innate adaptive immune responses to facilitate tumour clearance. Reovirus is safe, well tolerated currently clinical testing for the treatment of multiple myeloma, combination with dexamethasone/carfilzomib. Activation natural killer (NK) has been observed after systemic delivery reovirus patients; however, ability OV potentiate NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC) unexplored. This study elucidates potential chronic lymphocytic leukaemia (CLL), both as a cytotoxic agent an immunomodulator. We demonstrate that reovirus: (i) directly against CLL, which requires replication-competent virus; (ii) phenotypically functionally activates patient via monocyte-derived interferon-α (IFNα)-dependent mechanism; (iii) enhances ADCC-mediated killing CLL anti-CD20 antibodies. Our data provide strong preclinical evidence support use immunotherapy CLL.
core.ac.uk
nature.com
sci-hub.se 参考文章(62)
HW Ziegler-Heitbrock, R Schlag, D Flieger, E Thiel, Favorable response of early stage B CLL patients to treatment with IFN-alpha 2. Blood. ,vol. 73, pp. 1426- 1430 ,(1989) , 10.1182/BLOOD.V73.6.1426.1426
Tomoki Todo, Active Immunotherapy Oncolytic Virus Therapy Using HSV-1 Advances in Experimental Medicine and Biology. ,vol. 746, pp. 178- 186 ,(2012) , 10.1007/978-1-4614-3146-6_14
Luca Bologna, Elisa Gotti, Fabio Da Roit, Tamara Intermesoli, Alessandro Rambaldi, Martino Introna, Josée Golay, Ofatumumab Is More Efficient than Rituximab in Lysing B Chronic Lymphocytic Leukemia Cells in Whole Blood and in Combination with Chemotherapy Journal of Immunology. ,vol. 190, pp. 231- 239 ,(2013) , 10.4049/JIMMUNOL.1202645
Fiona Errington, Lynette Steele, Robin Prestwich, Kevin J. Harrington, Hardev S. Pandha, Laura Vidal, Johann de Bono, Peter Selby, Matt Coffey, Richard Vile, Alan Melcher, Reovirus Activates Human Dendritic Cells to Promote Innate Antitumor Immunity Journal of Immunology. ,vol. 180, pp. 6018- 6026 ,(2008) , 10.4049/JIMMUNOL.180.9.6018
Neil E. Kay, Joyce Zarling, Restoration of impaired natural killer cell activity of B-chronic lymphocytic leukemia patients by recombinant interleukin-2. American Journal of Hematology. ,vol. 24, pp. 161- 167 ,(1987) , 10.1002/AJH.2830240207
K.J. Harrington, R.G. Vile, A. Melcher, J. Chester, H.S. Pandha, Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics Cytokine & Growth Factor Reviews. ,vol. 21, pp. 91- 98 ,(2010) , 10.1016/J.CYTOGFR.2010.02.006
Maria Fernanda Pascutti, Margot Jak, Jacqueline M. Tromp, Ingrid A. M. Derks, Ester B. M. Remmerswaal, Rachel Thijssen, Martijn H. A. van Attekum, Gregor G. van Bochove, Dieuwertje M. Luijks, Steven T. Pals, René A. W. van Lier, Arnon P. Kater, Marinus H. J. van Oers, Eric Eldering, IL-21 and CD40L signals from autologous T cells can induce antigen-independent proliferation of CLL cells Blood. ,vol. 122, pp. 3010- 3019 ,(2013) , 10.1182/BLOOD-2012-11-467670
Evanthia Galanis, Svetomir N Markovic, Vera J Suman, Gerard J Nuovo, Richard G Vile, Timothy J Kottke, Wendy K Nevala, Michael A Thompson, Jean E Lewis, Kandelaria M Rumilla, Victoria Roulstone, Kevin Harrington, Gerald P Linette, William J Maples, Matt Coffey, James Zwiebel, Kari Kendra, Phase II Trial of Intravenous Administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in Patients with Metastatic Melanoma. Molecular Therapy. ,vol. 20, pp. 1998- 2003 ,(2012) , 10.1038/MT.2012.146
Sara Samuel, Vanessa F Tumilasci, Stephanie Oliere, Thi Liên-Anh Nguyên, April Shamy, John Bell, John Hiscott, VSV Oncolysis in Combination With the BCL-2 Inhibitor Obatoclax Overcomes Apoptosis Resistance in Chronic Lymphocytic Leukemia Molecular Therapy. ,vol. 18, pp. 2094- 2103 ,(2010) , 10.1038/MT.2010.188
Andrew T. Vaughan, Chisako Iriyama, Stephen A. Beers, Claude H. T. Chan, Sean H. Lim, Emily L. Williams, Vallari Shah, Ali Roghanian, Bjorn Frendéus, Martin J. Glennie, Mark S. Cragg, Inhibitory FcγRIIb (CD32b) becomes activated by therapeutic mAb in both cis and trans and drives internalization according to antibody specificity. Blood. ,vol. 123, pp. 669- 677 ,(2014) , 10.1182/BLOOD-2013-04-490821